PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)

Condition(s) targeted: Type 1 Diabetes

Intervention: Ramipril (Drug); Placebo (Drug); Placebo (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: Northwestern University

Official(s) and/or principal investigator(s):
Daniel Batlle, MD, Principal Investigator, Affiliation: Professor of Medicine and Chief Division of Nephrology/Hypertension

Overall contact:
Daniel Batlle, MD, Phone: 312-908-8342, Email: d-batlle@northwestern.edu

The purpose of this study is to determine if the early treatment with a blood pressure medication (an ACE Inhibitor) can prevent or delay the development of kidney disease (microalbuminuria) in patients with Type 1 diabetes who have normal blood pressure and urine albumin levels.

Official title: Nocturnal Hypertension and Prevention of Microalbuminuria in Type 1 Diabetes

Study design: Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study

Primary outcome: Development of microalbuminuria (high urine albumin). Hypertension, urine and blood markers will also be evaluated for assessment of kidney disease state.

Secondary outcome: We will assess changes in the relative stiffness of your arteries (endothelial dysfunction) in persons with type 1 diabetes over the 5year study.

Detailed description: Only a fraction of persons with Type 1 diabetes (less than 40%) develop diabetic kidney disease (nephropathy). When the urinary albumin (a protein normally excreted in small amounts) is within the normal range, the prevalence of high blood pressure (hypertension) based on office blood pressure readings is very low. Many of these persons, however, develop nocturnal hypertension (high nighttime blood pressure) before the development of abnormally high urinary albumin excretion (a condition referred to as microalbuminuria). Currently, early treatment with medications called ACE inhibitors is only recommended after there is an indication of kidney damage, as reflected by the presence of microalbuminuria. Beginning ACE inhibitor therapy is currently not recommended prior to the development of microalbuminuria, unless patients have high blood pressure, because it would result in over-treatment of many people. By the time that microalbuminuria develops, however, kidney damage may be present and many patients will develop kidney disease. It would therefore be beneficial to identify those subjects who will develop microalbuminuria, so that treatment could be started early for those individuals. Persons who may go on to develop protein in their urine and eventual kidney disease perhaps could be identified on the basis of an abnormal fall (too little) in blood pressure at night. This pattern should not be confused with high blood pressure, but instead seen as an early indication present before the development of high blood pressure and microalbuminuria.

The purpose of the current study is therefore aimed at demonstrating that it is possible to prevent kidney disease in patients with type 1 diabetes and normal office blood pressure and urine protein excretion by selecting them on the basis of an abnormal fall in blood pressure at night. Moreover, this clinical trial will reveal the impact of long-term administration of an ACE inhibitor on nighttime blood pressure and also assess changes in the relative stiffness of blood vessels(endothelial dysfunction) in persons with type 1 diabetes over time.

Minimum age: 13 Years. Maximum age: 50 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Subjects with type 1 diabetes confirmed by C peptide measurements.

- Male and Female subjects of all races will be included in this study.

- Subjects age must be between 13 to 50 years

- Duration of the disease (from time of diagnosis of diabetes) must be between 5 to 28

years.

- Subjects must be normotensive defined as a systolic blood pressure of ≤ 130 mmHg and

diastolic of ≤ 85 mmHg in subjects 18 and older and for children (ages 13-17) blood pressure will be in the normal range based on standard tables which takes in to account gender, height and age.

- The mean 24 blood pressure must meet the same criteria as the office blood pressures

outlined above.

- Subject must have normoalbuminuria (UAE < 30 mg/24 hrs)

- If subject is a female she must not be breast-feeding, and not of child-bearing

potential, defined as post-menopausal for at least 1 year or surgically sterile; if she is of child bearing potential, then she must be practicing one of the following methods of birth control: 1) condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD), 2) contraceptives (oral or parenteral) initiated three months prior to study drug administration, 3) maintain a monogamous relationship with a vasectomized partner, or 4) total abstinence from sexual intercourse.

Exclusion Criteria:

- Type 2 diabetics and other types of diabetics such as those with maturity onset

diabetes or the young (MODY) will be excluded on the basis of established clinical criteria.

- Subjects who have a history of hypertension or is taking any hypertensive

medications.

- Females who are pregnant or express a desire to become pregnant during the study.

Females who are breast-feeding. Refer to details in inclusion criteria above regarding females.

- Subjects who have a history of taking ACE inhibitors within the last six months or

have a current indication for ACE inhibitor therapy.

- Subjects (18 years of age and over) with a current blood pressure above

130mmHg/85mmHg. Subjects (13-17 years of age) who do not meet the normal range based on the standard tables

- Subjects who are currently microalbuminuric i. e. 24hr albumin > 30mg

- Subjects who have participated in an interventional clinical trial involving ABPM 6

months prior to this study.

- Subjects that have a diagnosis of chronic atrial fibrillation.

- Subjects with a lifestyle that would disrupt normal circadian rhythm (i. e.

night-shift workers).

- Subjects with a current serious co-morbid condition for which life expectancy is <2

years.

- Subjects with a history of non-compliance, or psychiatric disturbance that would

preclude successful completion of the study.

- Inability to give informed consent.

Daniel Batlle, MD, Phone: 312-908-8342, Email: d-batlle@northwestern.edu

University of Florida, Gainesville, Florida 32611, United States; Not yet recruiting
Karre Wetherington, CCRP, Phone: 352-334-1469, Email: kwether@UFL.EDU
Janet Silverstein, MD, Principal Investigator
Micahel Haller, MD, Sub-Investigator
Loreen Loreen, MD, Sub-Investigator
Henry (Hank) Rohrs, MD, Sub-Investigator
Toree Malasanos, MD, Sub-Investigator
Lisa Gallo, MD, Sub-Investigator
Desmond Schatz, MD, Sub-Investigator
Sally Humphrey, ARNP, Sub-Investigator

Northwestern University Feignberg School of Medicine, Chicago, Illinois 60611, United States; Recruiting
Daniel Batlle, Phone: 312-908-8342, Email: d-batlle@northwestern.edu
Jacqui van Twest, BS, MS, Phone: 312-908-6888, Email: preventkd@northwestern.edu or j-van-twest@northwestern.edu
Daniel Batlle, MD, Principal Investigator
Mark Molitch, MD, Sub-Investigator
Daniel Dunham, MD, Sub-Investigator
Vincent Yang, MD, BS, Sub-Investigator
William Schlueter, MD, Sub-Investigator
Craig Langman, MD, Sub-Investigator
Jennifer Tuazon, MD, Sub-Investigator

Evanston Northwestern Healthcare, Evanston, Illinois 60077, United States; Not yet recruiting
Herman Blomeier, MD, Phone: 847-663-8540, Email: h-blomeier@md.northwestern.edu
Mary Andreoni, Phone: 847-663-8540, Email: MAndreoni@enh.org
Lisa Purdy, MD, Principal Investigator
Herman Blomeier, MD, Sub-Investigator

Loyola University Chicago, Maywood, Illinois 60153, United States; Recruiting
Barbara Sexton, RN, MS, Phone: 708-216-8223, Email: bsexton@lumc.edu
Maryann Emanuele, MD, Principal Investigator
Carla Minutti, MD, Sub-Investigator

Rush University Medical Center, Endocrinology Section, Chicago, Illinois 60612, United States; Recruiting
Maripaz Vazquez, Phone: 312-942-6163, Email: Alexander_Lurie@rush.edu>
Alexander Lurie, MD, Principal Investigator
David Baldwin, MD, Sub-Investigator

University of Chicago, Chicago, Illinois 60637, United States; Not yet recruiting
George Bakris, MD, Phone: 773-702-6138, Email: gbakris@medicine.bsd.uchicago.edu
George Bakris, MD, Principal Investigator
Lou Philipson, MD, Sub-Investigator

University of Illinois at Chicago, Chicago, Illinois 60612, United States; Not yet recruiting
Felecia Gilet, CRC, Phone: 312-355-4442, Email: fgilet@uic.edu
Barengolts Elena, MD, Principal Investigator
Theodore Mazzone, MD, Sub-Investigator
Diego Ize-Ludlow, MD, Sub-Investigator
Terri Washington, MD, Sub-Investigator
Kristen Webb, NP, Sub-Investigator
Songya Pang, MD, Sub-Investigator

Northwestern Feinberg School of Medicine website: application form, general and contact information

PREVENTKD website: for study coordination

Related publications:

Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, Batlle D. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med. 2002 Sep 12;347(11):797-805.

Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hond E, McCormack P, Staessen JA, O'Brien E. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005 Jul;46(1):156-61. Epub 2005 Jun 6.

Lurbe A, Redón J, Pascual JM, Tacons J, Alvarez V, Batlle DC. Altered blood pressure during sleep in normotensive subjects with type I diabetes. Hypertension. 1993 Feb;21(2):227-35.

Haller MJ, Stein J, Shuster J, Theriaque D, Silverstein J, Schatz DA, Earing MG, Lerman A, Mahmud FH. Peripheral artery tonometry demonstrates altered endothelial function in children with type 1 diabetes. Pediatr Diabetes. 2007 Aug;8(4):193-8.

Starting date: July 2008
Ending date: September 2013
Last updated: October 29, 2008